key: cord-0009513-mxrp7dx1
authors: Belkacémi, Y.; Pène, F.; Touboul, E.; Rio, B.; Leblond, V.; Gorin, N. C.; Laugier, A.; Gemici, C.; Housset, M.; Ozsahin, M.
title: Total-body irradiation before bone marrow transplantation for acute leukemia in first or second complete remission: Results and prognostic factors in 326 consecutive patients
date: 1998
journal: Strahlenther Onkol
DOI: 10.1007/bf03038482
sha: bc0ce6cad2e48adc902b1621021833f3c0ecd158
doc_id: 9513
cord_uid: mxrp7dx1

AIM: In order to assess the influence of total-body irradiation (TBI) on the outcome and incidence of complication after bone marrow transplantation (BMT), we retrospectively analyzed our patients treated for acute leukemia and conditioned with TBI prior to BMT. PATIENTS AND METHODS: Between 1980 and 1993, 326 patients referred to our department with acute non-lymphoblastic leukemia (ANLL, n=182) and acute lymphoblastic leukemia (ALL, n=144) in complete remission underwent TBI either in single dose (190 patients: 10 Gy administered to the midplane, and 8 Gy to the lungs [STBI]) or in 6 fractions (136 patients: 12 Gy on 3 consecutive days, and 9 Gy to the lungs [FTBI]) before BMT. The male-to-female ratio was 204/122 (1.67), and the median age was 30 years (mean: 30 ± 11, range: 3 to 63). The patients were analyzed according to 3 instantaneous dose rate groups: 118 patients in the LOW group (≤0.048 Gy/min), 188 in the MEDIUM group (> 0.048 and ≤ 0.09 Gy/min), and 20 in the HIGH group (> 0.09 cGy/min). Conditioning chemotherapy consisted of cyclophosphamide (CY) alone in 250 patients, CY and other drugs in 54, and 22 patients were conditioned using combinations without CY. Following TBI, allogeneic and autologous BMT were realized respectively in 118 and 208 patients. Median follow-up period was 68 months (mean: 67 ± 29, range: 24 to 130 months). RESULTS: Five-year survival, LFS, RI and TRM rates were 42%, 40%, 47%, and 24%, respectively. Five-year LFS was 36% in the STBI and 45% in the FTBI group (p = 0.17). It was 36% in the LOW group, 42% in the MEDIUM group, and 30% in the HIGH group (p > 0.05). Five-year RI was 50% in STBI, 43% in FTBI, 55% in LOW, 41% in MEDIUM, and 44% in HIGH groups (STBI vs. FTBI, p = 0.48; LOW vs. MEDIUM, p = 0.03: MEDIUM vs. HIGH, p = 0.68). TRM was not influenced significantly by the different TBI techniques. When analyzing separately the influence of fractionation and the instantaneous dose rate either in ANLL or ALL patients, no difference in terms of survival and LFS was observed. Fractionation did not influence the 5-year RI both in ANLL and ALL patients. However, among the patients with ANLL, 5-year RI was significantly higher (58%) in the LOW group than the MEDIUM group (31%, p = 0.001), whereas instantaneous dose rate did not significantly influence the RI in ALL patients. The 5-year TRM rate was significantly higher in allogeneic BMT group both in ANLL (37%) and ALL (37%) patients than those treated by autologous BMT (ANLL: 15%, ALL: 18%: p = 0.002 and 0.02, respectively). The 5-year estimated interstitial pneumonitis (IP) and cataract incidence rates were 22% and 19%, respectively, in all patients. IP incidence seemed to be higher in the HIGH group (46%) than the MEDIUM (19%, p = 0.05) or LOW (25%, p = 0.15) groups. Furthermore, cataract incidence was significantly influenced by fractionation (STBI vs. FTBI, 29% vs. 9%; p = 0.003) and instantaneous dose rate (LOW vs. MEDIUM vs. HIGH, 0% vs. 27% vs. 33%; p < 0.0001). Multivariate analyses revealed that the best factors influencing the survival were 1st CR (p = 0.0007), age ≤ 40 years (p = 0.003), and BMT after 1985 (p = 0.008). The RI was influenced independently only by the remission status (p = 0.0002). On the other hand, the TRM rate was lower in patients who did not experience graft-vs.-host disease (GvHD, p < 0.0001), and in those treated after 1985 (p = 0.0005). GvHD was the only independent factor involved in the development of IP (p = 0.01). When considering the cataract incidence, the only independent factor was the instantaneous dose rate (p = 0.0008). CONCLUSION: The outcome of BMT patients conditioned with TBI for acute leukemia was not significantly influenced by the TBI technique, and TRM seemed to be lower in patients treated after 1985. On the other hand, cataract incidence was significantly influenced by the instantaneous dose rate.

Total-body irradiation (TBI) combined to intensive chemotherapy plays an important role in the conditioning regimen before bone marrow transplantation (BMT) in the treatment of patients with acute leukemia and many other hematological malignancies [1, 3, 24, 26, 30, 41, [54] [55] [56] . Apart from acute toxicity, TBI may lead to late toxic effects, including pneumonitis, cataracts, renal complications, endocrinologic disturbances, secondary malignancies, and in children, growth retardation [4, 5, 9, 17, 18, 33, 40, 42, 43, 53, 65] . Despite this intensive chemo-and radiotherapeutic treatment, relapse is one of the major causes of death in patients undergoing BMT.

To assess the influence of TBI regimen on the outcome, we retrospectively evaluated our clinical data concerning 326 consecutive patients with acute leukemia in first or second complete remission (CR), conditioned with high-dose chemotherapy and single-dose or fractionated TBI, and who underwent allogeneic or autologous BMT.

A total of 326 patients with acute non-lymphoblastic leukemia (ANLL, n = 182) and acute lymphoblastic leukemia (ALL, n = 144) referred to the Department of Radiation Oncology of the H6pital Tenon, Paris, France, between 1980 and 1993 underwent TB1 either in single dose (STBI, n = 190) or in 6 fractions (FTBI, n = 136) before BMT.

There were 204 male and 122 female patients, and the male-to-female ratio was 1.67. Their ages ranged from 3 to 63 years (mean: 30 +_ 11; median: 30) . The patients were analyzed according to 3 instantaneous dose rate groups: 118 patients in the LOW group (_<0.048 Gy/min), 188 in the MEDIUM group (> 0.048 and _< 0.09 Gy/min), and 20 in the HIGH group (> 0.09 Gy/min). All patients were in CR: 239 in their first CR (73%) and 87 in second CR (27%). Following TBI, allogeneic or autologous BMT was performed in 118 and 208 patients, respectively. There was no difference in terms of age distribution either between the STBI (mean: 31 _+ 11 years) and the FTBI (mean: 29 _+ 12 years) groups, or between the LOW (mean: 29 _+ 12 years), MEDIUM (mean: 31 _+ 11 years), and HIGH (mean: 29 +_ 11 years) groups. However, ALL patients (mean: 27 _+ 12 years) were younger than ANLL patients (mean: 32 _+ 10 years; p < 0.001). The patients were homogeneously distributed in terms of type of BMT, type of leukemia, and remission status in the 3 dose rate groups ( Table 1 ).

The follow-up period ranged from 24 to 130 months (median: 68; mean: 67 _+ 29 months). The mean followup period was 70 _+ 33 months in the STBI group, and 63 _+ 22 months in the FTBI group (p = 0.15). When considering the instantaneous dose rate groups, in the LOW group the mean follow-up period (55 _+ 28 months) was lower than in the MEDIUM (74 ___ 28 months; p < 0.001) and in the HIGH (77 _+ 14 months; p = 0.07) groups.

In the allogeneic BMT patient group (n = 118), the GvHD prophylaxis consisted of methotrexate in 31 pa- 

The details concerning our TBI technique are described elsewhere [36] . Single-dose TBI was done using a 6-MV linear accelerator (Neptune; GE-CGR, Buc, France) with horizontal beams (patient lying on his side, and irradiated anteriorly and posteriorly). The total dose administered to the midplane at the level of L4 was 10 Gy in 1 day, and the lung dose was limited to 8 Gy by partial shielding. Fractionated TBI was done in 6 fractions over 3 consecutive days, with a teletherapy unit (Alcyon; GE-CGR, Buc, France) using vertical beams (anterior and posterior ports, patient lying in prone and supine positions). A total dose of 12 Gy was delivered to the midplane (level of L4), and the lung dose was limited to 9 Gy by partial shielding. [31] .

Means were compared by Student's t-test. Proportions were compared using the )r test for values greater than 5, and Fisher's exact test for those less than or equal to 5. Kaplan-Meier [25] product-limit estimates were used to evaluate the survival, leukemia-free survival (LFS), relapse incidence (RI), treatment-related mortality (TRM), and the complication rates such as interstitial pneumonitis (IP) and cataract incidence rates. The events were death (all causes of death included) for overall survival, relapse for RI, and relapse and/or death for LFS. When computing the TRM, the event was considered by all causes of death except relapses (patients who relapsed were censored at time of death), and for the IP and cataract incidence rates, patients who died without having developed IP or cataract were censored at time of death. The analysis of the data was realized in July 1994. Differences between groups were assessed using the logrank test [38] . Confidence intervals (CI) were calculated from standard errors. Multivariate analyses were done using the Cox stepwiseregression analysis to determine the independent contribution of each prognostic factor thought to be influencing the different analyzed events [16] . (Table 2) . Among the patients with ANLL, neither the fractionation nor the instantaneous dose rate seemed to influence the survival, whereas in the A L L group, patients receiving FTBI did better (45.1%) than those receiving STBI (27.2%, p = 0.02). The 5-year survival rates in different groups are shown in Table 2 , and the causes of death in Table 3 .

In all patients, the 5-year LFS was 39.5% (95% CI, 34% to 45%) ( Figure 1 ). It was 35.8% in the STBI group, 44.7% in the FTBI group, 36.4% in the L O W group, 42.3% in the M E D I U M group, and 30% in the H I G H group ( Table 2 ). The 5-year LFS rates in different groups are presented in Table 2 . 

The 5-year TRM was 23.7% (95% CI, 19% to 29%) for all patients (Figure 1 ). When considering all patients together, no statistically significant difference was observed between the different TBI regimens (Table 2 ). However, in the A N L L group of patients, it was lower in the LOW group (12.5%) than in the M E D I U M (27.5%, p = 0.03) or H I G H (25%, p = 0.49) groups ( Figure 2 ). In the A L L patients, patients irradiated with FTBI (17%) had lower TRM rate than those irradiated with STBI (35.3%, p = 0.02) ( Figure 3 ). When considering the type of BMT, patients treated with autologous BMT did better than those treated with allogeneic BMT, both in the ANLL and A L L group of patients (Table 2) (Figure 4) . The 5-year TRM rates in different groups of patients are shown in Table 2 .

Besides the TBI technique (fractionation and instantaneous dose rate), various prognostic factors, including gender, age, type of leukemia, type of conditioning chemotherapy (CY alone vs. other drugs _+ CY), remission status (1st CR vs. 2nd CR), presence or not of GvHD in allogeneic BMT patients, time from diagnosis to transplantation (6 months or Jess vs. more than 6 months), and year of BMT (before or during 1985 vs. after 1985), were first analyzed in univariate analyses ( Table 2) to determine their influence on RI, survival, LFS, and TRM, then stepwise multivariate analyses (Cox regression model) were realized using the same parameters (Table 4 ). Both fractionation and instantaneous dose rate had no significant influence on the outcome after adjustment for other prognostic factors. When considering all patients together, the only independent factor influencing the RI was the remission status (p = 0.0002). Survival was influenced independently by the remission status (p = 0.0007), age (p = 0.003), and year of BMT (p = 0.008). The factors influencing independently the LFS were remission status (p = 0.003), and age (p = 0.01). On the other hand, TRM was significantly lower in patients who did not experience GvHD (p < 0.0001), and in those treated after 1985 (p = 0.0005). When analyzing separately the patients with A N L L or ALL, remission status was the only independent factor influencing the RI (respectively, p = 0.03 and 0.003), survival (respectively, p = 0.004 and 0.01), or LFS (respectively, p = 0.01 and 0.02) in both groups. Both in ANLL and A L L patients, TRM was influenced independently by 2 prognostic factors: year of BMT (p = 0.006 for ANLL, and p = 0.03 for ALL patients) and the presence of GvHD (p = 0.01 for ANLL, and p = 0.001 for A L L patients). (Figure 5a ). When considering the instantaneous dose rate, none of 118 patients in the LOW group, 23 (12%) of 188 patients in the MEDIUM group, and 2 (10%) of 20 patients in the HIGH group had cataracts (p = 0.0004), with a 5-year estimated incidence of 0%, 26.5%, and 33.3%, respectively (p < 0.0001) ( Figure  5b ). Among the patients who received steroids (n = 181), the 5-year cataract incidence rate was 19.4% compared to 29.6% in those who did not (p = 0.28). On the other hand, patients (n = 116) who received heparin as VOD prevention had significantly lower cataract incidence (10.3%) than those did not (23%, p = 0.03). The Cox stepwise multiple-regression model used to investigate the influence of fractionation, instantaneous dose rate, year of treatment, type of BMT, type of conditioning chemotherapy, presence or not of GvHD, use of steroids, use of heparin, gender, and patient age revealed that the only independent factor influencing the occurrence of cataracts was the instantaneous dose rate (p = 0.0008). [16/118] in allogeneic BMT vs. 10% [21/208] in autologous BMT; p = 0.44). On the other hand, VOD incidence was significantly lower (8%, 21/250) in patients whose conditioning chemotherapy consisted of CY alone than in those conditioned by other drugs + CY (21%, 16/76; p = 0.005). Moreover, patients treated before or during 1985 had significantly higher incidence of VOD (15 of 79 patients) than those treated after 1985 (22 of 247 patients, p = 0.02). Multivariate logistic regression analysis revealed that the only independent prognostic factor influencing the occurrence of VOD was the type of conditioning chemotherapy (p = 0.003).

TBI, combined with high-dose chemotherapy and followed by allogeneic or autologous BMT, has become as a widely accepted and relatively effective treatment modality for acute leukemia [1, 3, 10, 24, 49, 54, 551 . TBI plays an important cytoreductive role in this treatment that may be associated with toxicity, especially with the development of IP, VOD, and cataracts [6, 11, 18, 20, 23, 31, 33, 35, 48, 51, 57, 65] . However, patients conditioned with busulfan instead of TBI have earlier toxicity and increased TRM, and especially in adults and patients with advanced disease TBI-containing conditioning regimens are reported to be better [41] .

It is a generally accepted fact that leukemic cells and their normal counterparts are highly radiosensitive [27] . Although the data reported over the years generally confirm a high radiosensitivity and low repair capacity of leukemic stem cells, a number of exceptions have also been observed: decreasing the dose rate or increasing the number of fractions could affect the repair capacity of the leukemic cells [28, 39, 50] . The experimental data suggest that a fractionated scheme or low dose rate irradiation would probably be less effective against leukemia than STBI delivering the same dose, or high dose rate TBI [59] [60] [61] . However, clinical data do not show a higher incidence of relapse with the use of low dose rate and/or fractionated TBI [I0, 26, 36, 55] , with the exception of a few reports [44] . On the other hand, 15-Gy hyperfractionated TBI is reported to be more effective in terms of leukemic cell kill than 10-Gy (4 to 7 cGy/min) STBI [46] . Nevertheless, relatively small changes in the TBI dose have been reported to be an influencing factor on mixed hematopoietic chimerism following T-cell-depleted allogeneic BMT, which could influence the relapse rate [12] . Furthermore, it is even reported that hematopoietic recovery after 10-Gy acute TBI in a radiation accident was possible without BMT [2] . Our data revealed that, when considering the influence of fractionation in all patients, no difference was observed between the STBI and FTBI groups in terms of RI. However, when considering the instantaneous dose rate, patients in the LOW group had higher 5-year RI than those in the MEDIUM (p = 0.03) or HIGH (p = 0.11) groups. Both in the ANLL and ALL group of patients, fractionation did not significantly influence the RI. When considering the instantaneous dose rate separately in the ANLL patients, the 5-year RI was significantly higher in the LOW group than in the MEDIUM group (p = 0.001), whereas the instantaneous dose rate did not seem to influence the RI in ALL patients (Table 2 ). Malignant cells in ANLL could be more sensitive to the changes in the TBI dose rate than those in ALL, which was also demonstrated by the experimental studies [39, 59] . However, following the adjustment with various prognostic factors, multivariate analyses revealed that the only independent factor significantly influencing the RI was the remission status, either in all patients or separately in ANLL and ALL patients.

Theoretically, the therapeutic index is increased with better preservation of healthy tissues when using low dose rate and/or fractionation [21, 22, 52] . The choice of an optimal TBI regimen depends on several factors, including the technical difficulties (e. g., type and energy of treatment machine, time spent in low dose rate TBI, fractionation taking up the machine time for more than 1 day). When considering the late complications and the TRM, fractionated or hyperfractionated TBI seems to be better than single-dose TBI [15, 20, 45, 47, 48, 51] , as well as low dose rate TBI better than high dose rate TBI [3, 4, 40, 58] . In our study, the main causes of TRM were GvHD, IP, VOD, and infections. Animal experiments demonstrated clear improvement in dogs treated with autologous BMT conditioned with fractionated TBI [19] . TBI was reported to be an important factor influencing the TRM. According to Vrieseudorp [62, 63] , there is an important sparing of normal tissues like lung and intestines to be expected with more fractionated regimens. Cliff et al. [13] reported that increasing the dose of fractionated TBI from 12 to 15.75 Gy increased the TRM. The Seattle group [55] observed a significant survival advantage in patients treated with fractionated TBI, with a lower death rate related to non-leukemia related causes. Sutton et al. [51] concluded that the only independent predictive factor influencing the TRM was the TBI regimen (fractionated vs. single dose) in their series of 184 adult acute leukemia patients in first CR trans-planted with allogeneic BMT. In our series, stepwise multivariate analyses concluded that the TBI regimen was not a significant factor affecting survival and LFS when analyzing either all patients together, or ANLL and A L L patients separately. The same multivariate analysis revealed that the 2 independent predictive factors influencing the TRM rate were the year of BMT and the presence of GvHD, which was strongly related with allogeneic BMT (Table 4 ). One possible explanation for a lower incidence of TRM in patients treated after 1985 is the GvHD prophylaxis: after 1985, the majority of our patients transplanted with allogeneic BMT received a combination of cyclosporine and methotrexate, which is reported to decrease the incidence of GvHD in several studies [29] .

Interstitial pneumonitis is one of the most important post-BMT complications. It involves mostly the pulmonary interstitium as a mononuclear cell infiltration and relatively moderate fluid accumulation. GvHD seems to be the leading cause of IP in patients treated with allogeneic BMT [4, 14, 30, 51, 65] . There is also evidence that IP is influenced independently by the total TBI dose, total dose to the lungs, dose rate, and fractionation. However, irradiation is not the only cause. The International Bone Marrow Transplantation Registry data, in which doses delivered to the lungs and the use or not of pulmonary shielding were not thoroughly analyzed, showed no correlation between the type of TBI used and the incidence of IP [65] . CY given 24 h before or after TBI could also affect the incidence of IP [66] , and the effect of CY on radiation pneumonitis seems to be dose dependent [37, 66] . In the randomized trial of the Seattle group [55] , the IP incidence was not found to be significantly different between the single-dose (10 Gy in 1 day, 6 cGy/min) and fractionated TBI (2 Gy x 6 fractions, 1 fraction/day) groups. Shank et al. [47, 48] observed a clear decrease in IP incidence with hyperfractionated TBI (15 Gy, 6 to 19 cGy/min, 1.25 Gy 3 times a day) compared to single-dose TBI (10 Gy). Kim et al. [26] compared 2 different TBI regimens in ANLL patients treated with allogeneic BMT. Thirtysix patients were conditioned with STBI (7.5 Gy, 25 cGy/min), and 48 using hyperfractionated TBI (13.2 Gy, 1.65 Gy twice a day, 10 cGy/min). They did not find any difference in IP incidence between the 2 groups. Others have postulated that low dose rate STBI (about 5 to 6 cGy/min) is less toxic [3, 4, 40] . In our previously reported series [36] , which was randomized on 2 different instantaneous dose rates in 157 patients with various hematological malignancies, neither dose rate (3 vs. 6 cGy/min in FTBI, 6 vs. 15 cGy/min in STBI) nor fractionation (STBI vs. 6 x 2 Gy over 3 consecutive days) significantly influenced the IP incidence. GvHD remains an important complication following allogeneic BMT [64] , and its incidence does not seem to be related with the TBI regimen. Our present study shows that the 5-year IP incidence was influenced neither by fractionation nor by the type of BMT, but its incidence seemed to be higher in the HIGH group (46%) compared to the MEDIUM (19%, p = 0.05) or LOW (25%, p = 0.15) groups. In the allogeneic BMT group, GvHD influenced significantly the 5-year IP incidence (40% in GvHD+ vs. 18% in GvHD-patients, p = 0.04), and it was the only independent factor involved in the development of IP (p --0.01) in multivariate analysis. Moreover, in a recent analysis of an homogeneous series of 186 autologous BMT patients, which exclude the effect of GvHD, we reported a significant influence of instantaneous dose rate on the IP incidence, both in the univariate and in multivariate analyses [34] .

Among the other numerous complications following BMT, VOD of the liver is an early life-threatening syndrome directly caused by the conditioning regimen, which usually consists of TBI and single-or multiagent high-dose chemotherapy [31] . Several factors like pretherapeutic hepatic condition, the use of different chemotherapeutical agents and the irradiation dose can influence the risk of VOD [31, 32, 34] . Deeg et al. [20] reported a VOD incidence of 52% after 10-Gy STBI vs. 19% after 12-Gy FTBI (p = 0.02). Cosset et al. [15] , in their non-randomized comparison between single-dose and fractionated TBI, found a better therapeutic index favoring fractionated TBI in terms of VOD. Others report a decrease in the VOD incidence with a dose rate below 6 cGy/min both in animal experiments [58] and retrospective studies [3] . Ganem et al. [23] , in their series of 151 allogeneic BMT patients conditioned with high-dose chemotherapy and STBI (10 Gy, 3 cGy/min), found that the only independent factors influencing the incidence of VOD were high serum transaminase levels before BMT, and female gender. Neither in our previous randomized [36] nor in our non-randomized [8] studies did we observe any influence of TB! regimen on VOD incidence. Furthermore, the type of medical prevention did not have an influence on the latter's incidence.

Cataract formation in the crystalline lens of the eye is a well-recognized complication in patients treated with TBI [7, 11, 18, 26, 33, 57] . Deeg et al. [18] , in their series of 181 BMT patients conditioned with BelkacOmi et aL: Total-Body Irradiation prior to Bone Marrow Transplantation for Acute Leukemia TBI, observed 70 cataracts during a median follow-up period of 47 months for single-dose, and 30 months for fractionated TBI regimens using a dose rate from 4 to 8 cGy/min. The estimated cataract incidence (80% in STBI vs. 19% in FTBI) was significantly different between the 2 groups. Kim et al. [26] observed 15 cataracts from 10 to 60 months (12/36 in STBI0 median follow-up: 107 months; 3/48 in hyperfractionated TBI, median follow-up: 27 months) in 84 patients, with a 3-year estimated incidence of 27% in STBI group compared with 12% in the hyperfractionated TBI group (p > 0.05). Calissendorff and Bolme [11] reported that, in their series of 43 pediatric leukemia patients, all children who were followed for at least 3 years (n = 37) developed cataracts following STBI (10 Gy, 4 cGy/min). The Basel group [57] concluded that lens opacification developed later in fractionated TBI patients than in STBI patients, and progression of the lens opacification was slower (p < 0.01). In our prospective study of 157 patients randomized according to instantaneous dose rate both in STBI and FTBI regimens, the instantaneous dose rate and fractionation significantly influenced the 5-year estimated cataract incidence, but multivariate analysis, which took into consideration the influences of fractionation, dose rate, and steroid therapy, revealed that the only independent factor influencing the cataractogenesis was the instantaneous dose rate (p = 0.04) [33] . In our recent evaluation of 494 BMT patients with various hematological malignancies conditioned with either STBI or FTBI, we observed statistically significant differences in terms of 5-year cataract incidence between the STBI (34%) and the FTBI (11%, p = 0.0004) groups, as well as low (3.5%), medium (30%) and high (54%; low vs. medium, p = 0.0001; low vs. high, p < 0.0001) instantaneous dose rate groups [7] . Nevertheless, multivariate analysis revealed the protective effect on eyes of low instantaneous dose rate and intravenous administration of heparin against VOD. In the present series, 25 patients developed cataracts (20 in 190 patients in the STBI group and 5 in 136 patients in the FTBI group) during a median follow-up period of 68 months. When considering the 5-year estimated cataract incidence, in univariate analyses, both fractionation and instantaneous dose rate were found to influence cataract development ( Figure 5 ). The protective effect of heparin [7] , which was an interesting finding, could not be observed after the evaluation in multivariate analysis, which revealed that the only independent factor influencing cataractogenesis was the instantaneous dose rate (p = 0.0008).

In this retrospective evaluation of 326 acute leukemia patients, who underwent allogeneic or autologous BMT in their first or second CR and who were conditioned with single-dose or fractionated TBI using different instantaneous dose rates, we conclude that the outcome was not significantly influenced by the TBI technique, and the TRM seemed to be lower in patients treated after 1985 and in those who did not experience GvHD. IP incidence was also significantly influenced by the presence of GvHD. The addition of other drugs to cyclophosphamide in conditioning chemotherapy has been related to increased incidence of VOD of the liver. On the other hand, the cataract incidence was significantly influenced by the instantaneous dose rate.

Chemotherapy vs. marrow transplantation for adults with acute nonlymphoblastic leukemia: a five-year follow-up

Hematopoietic recovery after 10-Gy acute total body irradiation

Total body irradiation (TB1) before bone marrow transplantation in leukemia: a co-operative study from the European Group for Bone Marrow Transplantation

Interstitial pneumonitis following bone marrow transplantation after low dose rate total body irradiation

Late effects o1" total body irradiation

Maladie veino-occlusive du foie aprbs greffe de moelle osseuse: int6r6t possible du fractionnement de l'irradiation corporelle totale

Cataractogenesis after total-body irradiation

Is veno-occlusive disease influenced by the total-body irradiation technique

Growth and growth hormone secretion after bone marrow transplantation

AIIogeneic bone marrow transplantation after hyperfractionated total-body irradiation and cyclophosphamide in children with acute leukemia

Cataract development and outcome of surgery in bone marrow transplanted children

Effect of radiation dose on the development of mixed haemopoietic chimerism ff)llowing T cell-depleted allogeneic bone marrow transplantation

Allogeneic marrow transplantation in patients with chronic myeloid leukemia in the chronic phase: a randomized trial of two irradiation regimens

Pulmonary complications occurring after allogeneic bone marrow transplantation: a study of I30 consecutive transplanted patients

Single dose versus hyperfractionated total body irradiation before allogeneic bone marrow transplantation: a non randomized comparative study of 54 patients at the Institut Gustave-Roussy

Regression models and life tables

A Guide to Bone Marrow Transplantation

Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation

Single dose or fractionated total body irradiation and autologous marrow transplantation in dogs: effects of exposure tale, fiaction size and fractionation interval on acute and delayed toxicity

Total-Body Irradiation prior to Bone Marrow Transplantation for Acute Leukemia

Marrow transplantation for acute nonlymphoblastic leukemia in first remission: toxicity and longterm follow-up of patients conditioned with single dose or fractionated total body irradiation

Biological problems of total body irradiation

Modification of radiation-induced damage to bone marrow stem cells by dose rate, dose fractionation, and prior exposure to Cytoxan as judged by the survival of CFUs: Application to BMT

Venocclusive disease of the liver after allogencic bone marrow transplantation in man

Autologous bone marrow transplantation for acute myelocytic leukemia in first remission: a European survey of the role of marrow purging

Non-parametric estimation from incomplete observations

Comparison of two total body irradiation regimens in allogeneic bone marrow transplantation for acute non-lymphoblastic leukemia in first remission

Radiation response of human normal and leukemic hematopoietic cells assayed by in vitro colony formation

Radiobiological properties of human hematopoietic and stromal marrow cells

Prevention and treatment of acute graft-versus-host disease: the old and the new. A report from the Eastern Cooperative Oncology Group (ECOG)

Greffes de moelle allog6niques dans los leuc6mies aigu~s my61Ndes: 6tude rdtrospective chez 111 malades greffds en premi6re rdmission complbte

Venocclusive disease of the liver after bone marrow transplantation: diagnosis, incidence and predisposing factors

The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation

Total-body irradiation and cataract incidence: a randomized comparison of two instantaneous dose rates

Interstitial pneumonitis following bone-marrow transplantation conditioned with cyclophosphamide and total-body irradiation

Morbidity after total body irradiation

Total-body irradiation before bone marrow transplantation: results of two randomized instantaneous dose rates in 157 patients

ls body weight a risk factor of interstitial pneumonitis after bone marrow transplantation? Bone Marrow Transplant

Design and analysis of randomised clinical trials requiring prolonged observation of each patient: Part II

Effect of ffactionation and rate of radiation dose on human leukemic cells, HL-60

Increased mortality by septicemia, interstitial pneumonitis and pulmonary fibrosis among bone marrow transplant recipients receiving an increased mean dose rate of total body irradiation

A randomized trial comparing busulfan with total-body irradiation as conditioning in allogeneic marrow transplant recipients with leukemia: A report from the Nordic Bone Marrow Transplantation Group

Short-term endocrine consequences of total body irradiation and bone marrow transplantation in children treated for leukemia

Ovarian function following marrow transplantation for aplastic anemia or leukemia

Total body irradiation in acute myeloid leukemia and chronic myelogenous leukemia: influence of dose and dose-rate on leukemia relapse

Extended follow-up in 212 long-term allogeneic bone marrow transplant survivors

Hyperfractionation versus single dose irradiation in human acute lymphocytic leukemia cells: application to TBI for marrow transplantation

Hyperfractionated total body irradiation for bone marrow transplantation: results in seventy leukemia patients with allogencic transplants

Total body irradiation for bone marrow transplantation: the Memorial Sloan-Kettering Cancer Center experience

Autologous bone marrow transplantation for acute leukemia: results and prognostic factors in 90 consecutive patients

Radiobiological basis of total body irradiation with different dose rate and fractionation: repair capacity of hematopoietic cells

Allogeneic bone marrow transplantation for adult acute lymphoblastic leukemia in first complete remission: factors predictive of transplant-related mortality and influence of total body irradiation

Fractionation and dose rate effects in mice: a model for bone marrow transplantation

Late onset of renal dysfunction in survivors of bone marrow transplantation

The use and potential of bone marrow allograft and wholebody irradiation in the treatment of leukemia

Marrow transplantation for acute nonlymphoblastic leukemia in first remission using fractionated or singledose irradiation

Total body irradiation in preparation for marrow engraftment

Late ocular complications after bone marrow "~ransplantation

Effect of dose-rate on total body irradiation: lethality and pathologic findings

Radiation damage repair capacity of primary clonogenic blasts in acute lymphoblastic leukemia

Lack of CD24 antigen expression in B lineage acute lymphoblastic leukemia is associated with intrinsic radiation resistance of primary clonogenic blasts

AWT Konings etal. Radiation-dose fractionation and dose-rate relationships for long-term repopulating hemopoietic stem cells in a murinc bone marrow transplant model

Prediction of effects of therapeutic total body irradiation in man

Radiobiological speculations on therapeutic total body irradiation

Pathogenesis and pathology of graft vs. host disease

Interstitial pneumonitis after bone marrow transplantation: assessment of risk factors

Cyclophosphamide 24 hours before or after total body irradiation: effects on lung and bone marrow

For the Authors: Dr. Yazid Belkac~mi, Service d' Oncologie -RadiothOrapie, Hdpital Tenon, 4 rue de la Chine